Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb trial of PL-5 topical spray for secondary wound infection
ChiCTR2300071255Phase 3Completed
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jun 2023
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of peceleganan in Wound infection (WI) and burn wound infection (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Complete healing rate of the target wound on day 1 after the end of the last dose. Started Jun 2023; status: completed.
02
Drugs
peceleganan
03
Conditions
Wound infection (WI)burn wound infection
Beyond the preview
Go deeper on ChiCTR2300071255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071255.